RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
9995.HK
688331.SHG
Recent Articles
RemeGen hopes for pain relief from expanded drug uses
9995.HK
688331.SHG
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter